Top-Rated StocksTop-RatedMost-Upgraded StocksMost-UpgradedNASDAQ:INSM Insmed (INSM) Stock Price, News & Analysis → $5k to $1.3m in just 3 trades (From Insiders Exposed) (Ad) Free INSM Stock Alerts $65.58 +0.88 (+1.36%) (As of 06/18/2024 ET) Add Compare Share Share Today's Range$63.64▼$65.9850-Day Range$22.00▼$65.5852-Week Range$19.68▼$65.98Volume3.09 million shsAverage Volume5.98 million shsMarket Capitalization$9.75 billionP/E RatioN/ADividend YieldN/APrice Target$59.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Insmed alerts: Email Address Insmed MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside9.7% Downside$59.25 Price TargetShort InterestBearish7.31% of Shares Sold ShortDividend StrengthN/ASustainability-1.29Upright™ Environmental ScoreNews Sentiment0.84Based on 14 Articles This WeekInsider TradingSelling Shares$13.76 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.50) to ($3.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.13 out of 5 starsMedical Sector334th out of 913 stocksPharmaceutical Preparations Industry157th out of 430 stocks 2.5 Analyst's Opinion Consensus RatingInsmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 16 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInsmed has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Insmed's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.31% of the outstanding shares of Insmed have been sold short.Short Interest Ratio / Days to CoverInsmed has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insmed has recently increased by 9.37%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInsmed does not currently pay a dividend.Dividend GrowthInsmed does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsmed has received a 68.35% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Aminoglycosides", "Preclinical research services for physical health", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Insmed is -1.29. Previous Next 3.2 News and Social Media Coverage News SentimentInsmed has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Insmed this week, compared to 5 articles on an average week.Search Interest32 people have searched for INSM on MarketBeat in the last 30 days. This is an increase of 191% compared to the previous 30 days.MarketBeat Follows13 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is an increase of 44% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insmed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,762,062.00 in company stock.Percentage Held by InsidersOnly 4.60% of the stock of Insmed is held by insiders.Read more about Insmed's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Insmed are expected to grow in the coming year, from ($4.50) to ($3.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insmed is -12.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Insmed is -12.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Insmed's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media$16T Crypto Plot From Elon MuskReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Insmed Stock (NASDAQ:INSM)Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Read More INSM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INSM Stock News HeadlinesMay 31, 2024 | insidertrades.comInsmed Incorporated (NASDAQ:INSM) Insider John Drayton Wise Sells 7,852 SharesMay 28, 2024 | marketbeat.comInsmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024Stocks that are trading heavily or have substantial price changes on Tuesday: Insmed, Agios rise; DraftKings, Atlantica fallJune 19, 2024 | Crypto 101 Media (Ad)$16T Crypto Plot From Elon MuskReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.June 15, 2024 | americanbankingnews.comTraders Purchase Large Volume of Insmed Call Options (NASDAQ:INSM)June 14, 2024 | americanbankingnews.comInsmed (NASDAQ:INSM) Sets New 52-Week High at $63.23June 13, 2024 | americanbankingnews.comBrokers Set Expectations for Insmed Incorporated's Q2 2024 Earnings (NASDAQ:INSM)June 7, 2024 | prnewswire.comInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 5, 2024 | prnewswire.comInsmed To Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 19, 2024 | Crypto 101 Media (Ad)$16T Crypto Plot From Elon MuskReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.May 30, 2024 | prnewswire.comInsmed to Host Commercial Webinar on June 4, 2024May 30, 2024 | prnewswire.comInsmed Announces Pricing of $650 Million Public Offering of Common StockMay 29, 2024 | marketwatch.comInsmed Shares Extend Gains, Reach 23-Year HighMay 29, 2024 | finance.yahoo.comInsmed PT Raised to $67 at TD CowenMay 29, 2024 | msn.comInsmed’s stock should triple after positive drug trial data, analyst saysMay 29, 2024 | markets.businessinsider.comBuy Rating on Insmed: Anticipating Growth and Increased Stock ValueMay 29, 2024 | markets.businessinsider.comInsmed’s Promising Future: A Buy Rating with Increased Price Target Post-ASPEN Trial SuccessMay 28, 2024 | finance.yahoo.comInsmed stock blasts off over lung condition study resultsMay 28, 2024 | msn.comInsmed Stock More Than Doubled in Value Tuesday—Here’s WhyMay 28, 2024 | prnewswire.comInsmed Announces Proposed $500 Million Public Offering of Common StockMay 28, 2024 | investopedia.comInsmed Stock More Than Doubled in Value Tuesday—Here's WhyMay 28, 2024 | finance.yahoo.comInsmed Shares Rocket After Drug Eases Lung Disease SymptomsMay 28, 2024 | seekingalpha.comInsmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)May 28, 2024 | msn.comInsmed Stock More Than Doubles on Trial Win for Lung-Condition DrugMay 28, 2024 | finance.yahoo.comInsmed Stock Surges on Trial Win for Lung-Condition Drug. ‘We Hit the Mark,’ CEO Says.May 28, 2024 | proactiveinvestors.comInsmed shares skyrocket on positive trial results for lung drugMay 28, 2024 | investorplace.comWhy Is Insmed (INSM) Stock Up 134% Today?May 28, 2024 | marketwatch.comInsmed Shares Double on Positive Results for Brensocatib TrialSee More Headlines Receive INSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/19/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INSM CUSIPN/A CIK1104506 Webwww.insmed.com Phone908-977-9900Fax732-438-0381Employees373Year FoundedN/APrice Target and Rating Average Stock Price Target$59.25 High Stock Price Target$82.00 Low Stock Price Target$40.00 Potential Upside/Downside-9.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($5.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-749,570,000.00 Net Margins-236.74% Pretax Margin-235.89% Return on EquityN/A Return on Assets-56.78% Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.61 Sales & Book Value Annual Sales$305.21 million Price / Sales31.93 Cash FlowN/A Price / Cash FlowN/A Book Value($2.32) per share Price / Book-28.27Miscellaneous Outstanding Shares148,600,000Free Float141,769,000Market Cap$9.75 billion OptionableOptionable Beta1.12 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. William H. Lewis J.D. (Age 50)Pres, CEO & Chairman Mr. Paolo Tombesi (Age 55)Chief Financial Officer Ms. Christine A. Pellizzari J.D. (Age 51)Chief Legal Officer & Corp. Sec. Mr. Roger Adsett (Age 50)Chief Commercial Officer Dr. Paul D. Streck (Age 55)Advisor Key CompetitorsArena PharmaceuticalsNASDAQ:ARNAForty SevenNASDAQ:FTSVChemoCentryxNASDAQ:CCXIPTC TherapeuticsNASDAQ:PTCTTG TherapeuticsNASDAQ:TGTXView All CompetitorsInsiders & InstitutionsMartina M.D. FlammerSold 21,195 sharesTotal: $1.17 M ($55.00/share)Sara BonsteinSold 220,564 sharesTotal: $11.03 M ($50.00/share)John Drayton WiseSold 7,852 sharesTotal: $390,951.08 ($49.79/share)Ikarian Capital LLCBought 70,900 shares on 5/17/2024Ownership: 0.000%Comerica BankBought 48,327 shares on 5/17/2024Ownership: 0.033%View All Insider TransactionsView All Institutional Transactions INSM Stock Analysis - Frequently Asked Questions Should I buy or sell Insmed stock right now? 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last twelve months. There are currently 16 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INSM shares. View INSM analyst ratings or view top-rated stocks. What is Insmed's stock price target for 2024? 16 Wall Street research analysts have issued 12 month price objectives for Insmed's stock. Their INSM share price targets range from $40.00 to $82.00. On average, they expect the company's share price to reach $59.25 in the next year. This suggests that the stock has a possible downside of 9.7%. View analysts price targets for INSM or view top-rated stocks among Wall Street analysts. How have INSM shares performed in 2024? Insmed's stock was trading at $30.99 at the start of the year. Since then, INSM shares have increased by 111.6% and is now trading at $65.58. View the best growth stocks for 2024 here. When is Insmed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our INSM earnings forecast. How were Insmed's earnings last quarter? Insmed Incorporated (NASDAQ:INSM) posted its quarterly earnings data on Thursday, May, 9th. The biopharmaceutical company reported ($1.06) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.16. The biopharmaceutical company earned $75.50 million during the quarter, compared to analyst estimates of $77.76 million. The company's revenue was up 15.8% on a year-over-year basis. During the same period last year, the business earned ($1.17) EPS. What ETFs hold Insmed's stock? ETFs with the largest weight of Insmed (NASDAQ:INSM) stock in their portfolio include Simplify Health Care ETF (PINK), Virtus LifeSci Biotech Products ETF (BBP), BNY Mellon Innovators ETF (BKIV), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Franklin Genomic Advancements ETF (HELX), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Invesco Nasdaq Biotechnology ETF (IBBQ). What guidance has Insmed issued on next quarter's earnings? Insmed issued an update on its FY 2024 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $340.0 million-$360.0 million, compared to the consensus revenue estimate of $353.5 million. What is Will Lewis' approval rating as Insmed's CEO? 14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees. What other stocks do shareholders of Insmed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN). Who are Insmed's major shareholders? Insmed's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.77%), Price T Rowe Associates Inc. MD (7.25%), William Blair Investment Management LLC (2.84%), Bellevue Group AG (1.44%), Capital International Investors (1.09%) and Principal Financial Group Inc. (0.97%). Insiders that own company stock include David R Brennan, John Drayton Wise, Martina MD Flammer, Melvin Md Sharoky, Michael Alexander Smith, Orlov S Nicole Schaeffer, Roger Adsett, Sara Bonstein and William Lewis. View institutional ownership trends. How do I buy shares of Insmed? Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INSM) was last updated on 6/19/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredHistoric NVIDIA partnership could send this tiny AI stock soaring...After striking partnerships with trillion-dollar chipmaker NVIDIA... ARM surged over 60% in a week... Who's...Behind the Markets | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredThe biggest lie in America unravels…Americans have been fed an insidious lie for decades. Fortunately, it's starting to unravel – and a few powerf...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
